科伦博泰重磅药物，获批新适应症！

药通社02-08

2月6日，NMPA官网显示，科伦博泰TROP2 ADC芦康沙妥珠单抗获批一项新适应症，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性（HR+）且人表皮生长因子受体2阴性（HER2-）乳腺癌（BC）成人患者。此前该适应症已被 CDE 纳入优先审评审批程序。芦康沙妥珠单抗是科伦博泰研发的一款靶向TROP2的ADC药物，由人源化单克隆抗体 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609352096?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-08 12:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2609352096","market":"hk","top_or_hot":-1,"title":"科伦博泰重磅药物，获批新适应症！","media":"药通社","content":"<div>\n<p>2月6日，NMPA官网显示，科伦博泰TROP2 ADC芦康沙妥珠单抗获批一项新适应症，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性（HR+）且人表皮生长因子受体2阴性（HER2-）乳腺癌（BC）成人患者。此前该适应症已被 CDE 纳入优先审评审批程序。芦康沙妥珠单抗是科伦博泰研发的一款靶向TROP2的ADC药物，由人源化单克隆抗体 ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208124748a48a1ddb&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦博泰重磅药物，获批新适应症！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦博泰重磅药物，获批新适应症！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-08 12:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208124748a48a1ddb&s=b><strong>药通社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2月6日，NMPA官网显示，科伦博泰TROP2 ADC芦康沙妥珠单抗获批一项新适应症，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性（HR+）且人表皮生长因子受体2阴性（HER2-）乳腺癌（BC）成人患者。此前该适应症已被 CDE 纳入优先审评审批程序。芦康沙妥珠单抗是科伦博泰研发的一款靶向TROP2的ADC药物，由人源化单克隆抗体 ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208124748a48a1ddb&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208124748a48a1ddb&s=b","article_id":"2609352096","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208124748a48a1ddb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609352096","pubTimestamp":1770523610,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2月6日，NMPA官网显示，科伦博泰TROP2 ADC芦康沙妥珠单抗获批一项新适应症，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性（HR+）且人表皮生长因子受体2阴性乳腺癌成人患者。2022年5月，科伦博泰与默沙东签署合作协议，授予后者在大中华区以外的所有地区开发、使用、制造及商业化芦康沙妥珠单抗的独家权利。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06990":"科伦博泰生物","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK1161":"生物科技"},"translate_title":"Kelun Botai's blockbuster drug has been approved for new indications!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9},"content_text":"2月6日，NMPA官网显示，科伦博泰TROP2 ADC芦康沙妥珠单抗获批一项新适应症，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性（HR+）且人表皮生长因子受体2阴性（HER2-）乳腺癌（BC）成人患者。此前该适应症已被 CDE 纳入优先审评审批程序。芦康沙妥珠单抗是科伦博泰研发的一款靶向TROP2的ADC药物，由人源化单克隆抗体 Sacituzumab、可酶促裂解的 Linker 和新型拓扑异构酶I抑制剂T030偶联而成，药物抗体比（DAR）平均高达7.4。2022年5月，科伦博泰与默沙东签署合作协议，授予后者在大中华区以外的所有地区开发、使用、制造及商业化芦康沙妥珠单抗的独家权利。2025年11月，默沙东宣布，黑石将支付7亿美元（不可退还，但需遵守协议中规定的终止条款）用于覆盖芦康沙妥珠单抗在2026年的部分研发成本。截至目前，默沙东已围绕芦康沙妥珠单抗在肺癌、乳腺癌、胃癌、妇科肿瘤多个领域开展16项III期全球性临床研究。监管审评方面，芦康沙妥珠单抗此前已经在国内获批3项适应症，本次为获批的第4项：2024年11月，获批用于既往至少接受过2种系统治疗（其中至少1种治疗针对晚期或转移性阶段）的局部晚期或转移性三阴性乳腺癌（TNBC）患者；2025年3月，获批用于治疗经EGFR-TKI和含铂化疗治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状NSCLC成人患者；2025年10月，用于治疗经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗后进展的EGFR 突变局部晚期或转移性NSCLC成人患者。来源：丁香园 Insight 数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609352096","isCrawlerRequest":true}